Dow

CARBOWAX™ SENTRY™ PEGs common applications include: carrier/plasticizer in gel capsules, base for face/neck lotions, providing formulation stability in toothpaste, binder for tablets, shampoo wetting agent, and more. CARBOWAX™ SENTRY™ PEGs are available in average molecular weights ranging from 300 ...

VERSENE™NA Chelating Agent is an effective stabilizer and preservative for pharmaceutical preparations, including medicated creams and ointments, ocular care, syrups and elixirs. This Edetate Disodium USP-grade product controls metal ions present in pharmaceutical formulations or processes. Product Bene...

Detailed impurity profiles are available for industrial grade solvents. In addition, multiple high purity solvents are available:
- Phenoxyethanol /DOWANOL™ EPh NF: CAS: 122-99-6
- Isopropyl Alcohol /Isopropanol AnhydrousUSP/EP: CAS: 67-63-0
- Propionic acid FC...

Large Molecule (Biologic) API Production:

Dow’s TRITON™ and TERGITOL™ surfactants are used to inactivate virus envelopes, lyse cells, and buffer RNA extraction solutions.  As the only producer of TRITON™ X-100 (CAS No: 9036-19-5), which has been trusted by the industry for decades...

View our interactive 2019 Sustainability Report to find out how we’re reaching beyond our company to help impact positive change in our business value chains and communities globally.

CARBOWAX™ and CARBOWAX™ SENTRY™ Polyethylene Glycols (PEGs) are highly versatile excipients and active pharmaceutical ingredients (APIs) produced to meet the exacting requirements of the pharmaceutical industry

CARBOWAX™ SENTRY™ LPEG and MPEGs are pharmaceutical excipients which can be used in the manufacturing of capsules as hydrophilic fillers for solubilization of the API, but also as plasticizer in the coating of the gelatin capsules.

The company intends to be carbon neutral by 2050

Enhance topical formulations with CARBOWAX™ SENTRY™ Polyethylene Glycols (PEGs)

The new facility is expected to come online by the end of 2021

Whether you’re in the business of small or large molecule API manufacture, we are here to support you. Dow delivers a wide range of solvents and a variety of surfactants - of TRITON™ X-100 and TERGITOL™ - used to inactivate virus envelopes, lyse cells, and buffer RNA extraction solutions

The company will expand capacity at its existing facility in Tarragona, Spain

Dow offers a range of solvents to address the needs of the highly regulated pharmaceutical industry. With Dow’s global sourcing, all of your manufacturing locations can receive the same high quality product with every order. Please visit our API manufacturing page and click on the brochure to selected products that are manufactured to Current Good Manufacturing Practices (cGMP), and meet additional requirements from the appropriate governing bodies. Industrial grades are also available with impurities disclosed upon request.

Dow fluid specialists can help you design, operate, and maintain your heat transfer system for optimum performance and economy. The family of DOWTHERM™ and SYLTHERM™ heat transfer fluids available from Dow are high performance products. The line includes two distinct fluid chemistries – synthetic organic and silicone. You’ll find an overview description of our full line of synthetic fluids, plus recommended applications on this brochure, including pharmaceutical industry.

This session was originally broadcast as part of the CPhI Worldwide 2021 digital content programme. One of the top priorities of pharmaceutical companies in bringing new products to market is to prove a drug substance is safe and effective against a certain illness. As you would expect, especially in the beginning stages of development, companies primarily focus on the API itself and not necessarily the excipients that will go into the final drug product. Instead, compendial requirements and guidelines such as those from ICH exist to ensure excipient quality and safety. Not only this is important from a regulatory perspective, but excipient quality can also impact product performance, even if those excipients meet all compendial requirements. In this session, you will learn about: Recent regulatory developments relating to residual impurities in pharmaceutical excipients Challenges in analytical methods to meet increasingly stringent targets How you can work with your excipient supplier to ensure high product quality